Verification Opinion of CITIC Securities Co., Ltd. on the Change of Fund Usage for the 2020 Private Placement of Haisco Pharmaceutical Group Co., Ltd.
CITIC Securities Co., Ltd. (hereinafter referred to as "CITIC Securities" or "the Sponsor") is the ongoing supervisory institution for the private placement of Haisco Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company" or "Haisco"). In June 2025, CITIC Securities took over the continuous supervision responsibilities from the previous sponsor, Huatai United Securities Co., Ltd., regarding the usage of unutilized raised funds.
According to relevant regulations including the "Administrative Measures for Sponsorship of Securities Issuance and Listing," "Shenzhen Stock Exchange Stock Listing Rules," and "Self-Regulatory Guidelines No. 1 for Listed Companies on the Shenzhen Stock Exchange - Standard Operation of Main Board Listed Companies," CITIC Securities conducted a verification of the change in fund usage for Haisco's 2020 private placement, the establishment of new special accounts for raised funds, and the provision of loans to wholly-owned subsidiaries for project implementation. The verification opinions are as follows:
I. Overview of the Fund Investment Projects
(1) Basic Situation of the Raised Funds
According to the China Securities Regulatory Commission's approval document (Zheng Jian Xu Ke [2022] No. 869), the Company issued 40,000,000 shares of ordinary shares (A shares) at an issuance price of RMB 20.00 per share, raising a total of RMB 800,000,000.00. After deducting various issuance expenses of RMB 9,133,782.42 (excluding tax), the actual net amount raised was RMB 790,866,217.58. The raised funds have been verified by Xinyong Zhonghe Accounting Firm (Special General Partnership), which issued the "Verification Report on the Raised Funds of Haisco Pharmaceutical Group Co., Ltd. for the 2020 Private Placement" (XYZH/2022CDAA5B0008) on January 16, 2023, and the funds have been stored in special accounts. For detailed information, please refer to the announcement numbered 2023-008 disclosed by the Company on February 2, 2023, on the Giant Tide Information Network and other media.
(2) Usage and Surplus of the Raised Funds
As of April 30, 2026, the balance of the raised funds in various bank special accounts is listed below:
| No. | Account Name | Opening Bank | Account Number | Balance of Raised Fund Account |
|---|---|---|---|---|
| 1 | Haisco Pharmaceutical Group Co., Ltd. Chengdu Bank Co., Ltd. Jinhe Branch | 1001300001076159 | 181.562 | |
| 2 | Bank of Communications Co., Ltd. Wenjiang Branch | 511511360013003804830 | 4,212.03 | |
| Total | 4,393.59 |
Note: The Company used RMB 12 million of idle raised funds in the Chengdu Bank Co., Ltd. Jinhe Branch account to subscribe to a 7-day notice deposit and RMB 170 million to subscribe to structured deposits. As of April 30, 2026, these funds have not been transferred back to the special account for raised funds supervision at Chengdu Bank Co., Ltd. Jinhe Branch.
As of April 30, 2026, the usage and surplus of the raised funds for investment projects are as follows: